|
Benralizumab: a unique IL-5 inhibitor for severe asthma
Dove Medical Press Abstract: The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%–10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic … |
View full post on asthma – Google News